Comparative study on the effects of orchiectomy or chronic administration of HOE 766 (GnRH-A) in patients with advanced prostatic adenocarcinoma

Koutsilieris, M.; Herrera, Ricardo; Stellos, A.; Dufresne, M.; Martínez, Álvaro; Ackman, Douglas; Fazekas, A. T. A.; Tolis, G.

doi:10.1016/0022-4731(84)90438-2

Journal of Steroid Biochemistry

1984

DOI: 10.1016/0022-4731(84)90438-2

|View full text |Cite

Comparative study on the effects of orchiectomy or chronic administration of HOE 766 (GnRH-A) in patients with advanced prostatic adenocarcinoma

M. Koutsilieris¹,

Ricardo Herrera²,

A. Stellos³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1985

1987

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Nasally administered buserelin inducing complete remission of lung metastases in male breast Cancer

Vorobiof

Falkson

1987

Cancer

View full text Add to dashboard Cite

A 60-year-old man with bilateral lung metastases from breast cancer was treated with the gonadotropin-releasing hormone analogue, buserelin, given as an intranasal spray. Androgen deprivation and complete remission of lung metastases were achieved with minimal side effects. Androgen deprivation by means of nasally administered buserelin offers an easy and efficient alternate approach in the treatment of metastatic male breast cancer.

show abstract

Nasally administered buserelin inducing complete remission of lung metastases in male breast Cancer

Vorobiof

Falkson

1987

Cancer

View full text Add to dashboard Cite

show abstract

Long‐term follow‐up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: Classification of variables associated with disease outcome

Koutsilieris

Tolis²

1985

The Prostate

View full text Add to dashboard Cite

We compared the clinical efficacy and safety of Buserelin treatment versus orchiectomy in 29 patients with newly diagnosed advanced prostatic cancer. There was no significant difference between the two treatment modalities in 1) reduction of plasma testosterone to below 100 ng/dl after 8 weeks, 2) objective clinical response rates in patients with stage D2 carcinoma, 3) induction of complete remission in patients with stages C and D1 carcinoma, or 4) relapse rates and death rates in patients with stage D2 carcinoma. After scoring stage D2 disease according to our aggressiveness analysis system, we found that patients with less aggressive neoplasms displayed a qualitatively better response and more prolonged remission. These data and the absence of estrogenic effects confirm Buserelin as a favorable alternative to orchiectomy in the treatment of prostatic cancer. Additionally, the study demonstrates the importance of considering the heterogeneity of the aggressiveness of stage D2 disease in assessing the benefits of clinical trials in prostatic carcinoma.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparative study on the effects of orchiectomy or chronic administration of HOE 766 (GnRH-A) in patients with advanced prostatic adenocarcinoma

Cited by 2 publications

References 0 publications

Nasally administered buserelin inducing complete remission of lung metastases in male breast Cancer

Nasally administered buserelin inducing complete remission of lung metastases in male breast Cancer

Long‐term follow‐up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: Classification of variables associated with disease outcome

Contact Info

Product

Resources

About